

Bio-Rad IH-reader 24 receives FDA clearance

30 October 2018 | News

A combination centrifuge and reader, the IH-Reader 24 automatically reads and transfers blood type and antibody screening results to Bio-Rad's IH-Com patient data management software, offering improved efficiencies for transfusion medicine laboratories that use manual methods to test blood.



Singapore – The FDA grants 510(k) clearance for Bio-Rad Laboratories' IH-Reader 24, a semi-automated blood typing system aimed at small-to-medium size labs. Bio-Rad Laboratories is a global provider of life science research and clinical diagnostics products.

A combination centrifuge and reader, the **IH**-Reader 24 automatically reads and transfers blood type and antibody screening results to Bio-Rad's **IH**-Com patient data management software, offering improved efficiencies for transfusion medicine laboratories that use manual methods to test blood. The system offers standardized interpretation of results that are independent of user assessment.

With the addition of the **IH**-Reader 24, Bio-Rad's portfolio of blood typing platforms offers transfusion medicine laboratories and lab networks of any size a way to standardize automated, semi-automated, and manual blood typing using products from one supplier.

"We are pleased to receive FDA clearance for the **IH**-Reader 24 and look forward to extending our reach in the U.S. transfusion medicine market," said John Hertia, Bio-Rad President, Clinical Diagnostics Group. "The system expands our offering in blood testing, allowing labs to choose the combination of Bio-Rad instruments and methods that best suit their budget and their workflow."

Bio-Rad offers a wide variety of platforms, reagents, data management, and connectivity solutions to address different blood typing needs, offering efficient and reliable results for blood grouping, phenotyping, crossmatching, antibody screening and identification, direct antiglobulin tests, and single antigen typing.